Last reviewed · How we verify
AV5080
AV5080 is a nucleoside analog that inhibits viral RNA-dependent RNA polymerase, blocking replication of RNA viruses.
AV5080 is a nucleoside analog that inhibits viral RNA-dependent RNA polymerase, blocking replication of RNA viruses. Used for Tick-borne encephalitis (TBE), Other flaviviral infections.
At a glance
| Generic name | AV5080 |
|---|---|
| Also known as | AV5080 at a daily dose of 160 mg |
| Sponsor | Viriom |
| Drug class | Nucleoside analog antiviral |
| Target | Viral RNA-dependent RNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
AV5080 is a broad-spectrum antiviral nucleoside that targets the RNA polymerase of enveloped RNA viruses. By incorporating into viral RNA during replication, it causes chain termination and prevents viral genome synthesis. This mechanism provides activity against multiple viral families including flaviviruses and other RNA viruses.
Approved indications
- Tick-borne encephalitis (TBE)
- Other flaviviral infections
Common side effects
- Gastrointestinal disturbances
- Elevated liver enzymes
- Headache
Key clinical trials
- Dose Range Study to Evaluate the Efficacy and Safety of AV5080 in Patients With Influenza (PHASE2)
- Study Evaluating the Efficacy and Safety of AV5080 in Patients With Uncomplicated Influenza (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AV5080 CI brief — competitive landscape report
- AV5080 updates RSS · CI watch RSS
- Viriom portfolio CI